Safety and Tolerability of Thrombin Inhibition in Scleroderma-Associated Interstitial Lung Disease.

Richard M SilverD A WilsonT AkterI AtanelishviliJ T HugginsK KajdaszK B HighlandP J NietertG S Bogatkevich

Published in: ACR open rheumatology (2019)

Dabigatran appears to be safe and well tolerated in patients with SSc-ILD. A larger randomized controlled trial to test the efficacy of direct thrombin inhibition with dabigatran can be considered.

Keyphrases

interstitial lung disease
systemic sclerosis
randomized controlled trial
rheumatoid arthritis
idiopathic pulmonary fibrosis
atrial fibrillation
study protocol
open label
systematic review
double blind
placebo controlled